To establish a novel and widely applicable payload-linker technology for antibody–drug
conjugates (ADCs), we have focused our research on applying exatecan mesylate (DX …

Antibody–drug conjugates (ADC) using DNA topoisomerase I inhibitor DXd/SN-38 have
transformed cancer treatment, yet more effective ADCs are needed for overcoming …

Trastuzumab conjugates consisting of exatecan derivatives were prepared and their
biological activities and physicochemical properties were evaluated. The ADCs showed …

Abstract Topoisomerase I (TOP1) Inhibitors constitute an emerging payload class to
engineer antibody–drug conjugates (ADC) as next-generation biopharmaceutical for cancer …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of anticancer therapeutics,
with 14 ADCs already approved worldwide. We developed unique linker technologies for …

B-cell lymphoma remains one of the most refractory tumors, and as such the development of
novel treatment approaches, such as antibody-drug conjugates (ADCs), is required. To …

Background: Topoisomerase I is an enzyme that plays a crucial part in DNA replication and
transcription by the relaxation of supercoiled double-stranded DNA. Topoisomerase I …

Antibody–drug conjugates (ADCs) that incorporate the exatecan derivative DXd in their
payload are showing promising clinical results in solid tumor indications. The payload has …

Abstract Antibody Drug Conjugate (ADC) is an emerging technology to overcome the
limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an …

The therapeutic efficacy of antibodies can be successfully improved through targeted
delivery of potent cytotoxic drugs in the form of antibody-drug conjugates. However …